Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.

Pierre JohansenBarrie ChubbBarnaby HuntSamuel J P MalkinAnna SandbergMatthew Capehorn

Published in: Advances in therapy (2020)

Once-weekly semaglutide 1 mg is a cost-effective treatment option versus once-daily liraglutide 1.2 mg, based on the SUSTAIN 10 trial, from a UK healthcare payer perspective.

Keyphrases

healthcare
physical activity
clinical trial
randomized controlled trial
study protocol
combination therapy